Navigation Links
REVEAL(R) RegistryData May Advance Patient Care in Pulmonary Arterial Hypertension
Date:5/17/2010

Link';s.eVar3=s.prop5;s.prop15='93936439';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.revealregistry.com/">www.revealregistry.com or call 1-877-REVEAL5 (877-738-3255).

About Actelion Ltd

Actelion Ltd is a biopharmaceutical company headquartered in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer® through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's 2000-plus employees focus on discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®).


'/>"/>
SOURCE Actelion Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
6. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
7. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
8. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
9. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
10. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
11. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Germany , March 5, 2015 ... today announced that the foundation has made a ... CureVac, a leading clinical-stage biopharmaceutical company specializing in ... the foundation will also provide separate funding for ... CureVac,s proprietary messenger RNA (mRNA) platform. In addition, ...
(Date:3/5/2015)... 5, 2015 CANTEL MEDICAL CORP. (NYSE: ... ended January 31, 2015 on Thursday, March 12 before the ... results at 11:00 AM ET. To participate ... 10 minutes before the beginning of the call. If you ... will be available from Thursday, March 12, 2015 through midnight ...
(Date:3/5/2015)... March 5, 2015   AMC Health , ... recognized for improving the effectiveness and efficiency of ... Robert Anazagasty and Jared Wilstead ... Vice President, Strategic Client Development, and Wilstead will ... support AMC Health,s commitment to accelerating the adoption ...
Breaking Medicine Technology:The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 2The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 3The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2AMC Health Bolsters Sales Team with Robert Anazagasty and Jared Wilstead 2AMC Health Bolsters Sales Team with Robert Anazagasty and Jared Wilstead 3
... Holdings, Inc. (NYSE: ZMH ; SIX: ZMH), a ... Board of Directors has approved the payment of a ... of 2012.  Zimmer,s Board of Directors also has authorized a ... opportunity to initiate a quarterly dividend results from our ...
... Dec. 19, 2011  Valeant Pharmaceuticals International, Inc. (NYSE: ... that effective December 16, 2011, the company completed ... unit of Sanofi (EURONEXT: SAN and NYSE: SNY). ... Valeant Pharmaceuticals International, Inc. (NYSE/TSX: ...
Cached Medicine Technology:Zimmer Initiates Quarterly Dividend and Announces New Share Repurchase Program 2Zimmer Initiates Quarterly Dividend and Announces New Share Repurchase Program 3
(Date:3/5/2015)... Supply & Demand Chain Executive Magazine has ... Know” in the supply chain industry, and we are ... team were included on this year’s list! Russ King ... due to their hard work, their commitment to excellence, ... resolving client needs and challenges. , Russ ...
(Date:3/5/2015)... 05, 2015 Dr. Jonathan Glashow a ... ) has been named by Castle Connolly ... area. Dr. Glashow has been selected by Castle Connolly ... the top specialty care doctors in the tri-state metropolitan ... Connolly program, which carefully screens and selects doctors through ...
(Date:3/5/2015)... As a result of the American ... Clearstream, LLC ’s products, services and company philosophies, ... products—led by their mPulse Hand Sanitizer—fits the core ... The AAPA—which represents a profession comprising than 100,000 ... specialties in the U.S.—advocates and educates on behalf ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Today, ... now running on 100% pollution-free electricity through a ... , As an Arcadia Power Clean Energy ... (EPA) Green Power Partnership requirements, joining national brands ... also purchase clean energy. Earth Source Organics joins ...
(Date:3/5/2015)... Park, California (PRWEB) March 05, 2015 ... (JCAP) last week released a special issue ... in the field of PANDAS (Pediatric Autoimmune Neuropsychiatric ... Neuropsychiatric Syndromes), an autoimmune reaction triggered by infections ... lyme, which result in inflammation of the child's ...
Breaking Medicine News(10 mins):Health News:MEBC Leaders Awarded Supply Demand Chain Executive Pros to Know Title For 2015 2Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 3Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 4Health News:Earth Source Organics to Run on Clean Energy from Arcadia Power 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 3
... has been found that elders in hospitals and care homes are ... this, many of them are said to be in hunger// for ... Ivan Lewis. ,Commencing the ‘Dignity for older people’ campaign ... people should be thoroughly understood. When the food is kept far ...
... Pennsylvania School of Medicine have described a new type ... the patient's thoughts, providing two-way signaling for motor control ... at a junction now of developing a new approach ... Smith, MD, Professor of Neurosurgery and Director of the ...
... Scientists have unlocked the secrets of a deadly superbug that attacks ... ,The news is a vital first step in attempts to ... resistant to current antibiotic treatments. ,Already responsible for ... stages of an epidemic that could result in a massive death ...
... study, published in the March 1, 2007 issue of CANCER, ... termination of this highly effective breast cancer drug may negatively ... that over one third of women have ceased tamoxifen treatment. ... quarter of women treated for breast cancer stop tamoxifen within ...
... traits shape up in natural populations,// but one is led ... Two theories have tried to address this challenge – the ... ,The theory of hitchhiking has indicated that genes ... in natural populations when they "hitch a ride" with healthier ...
... whatever the color”, says Dr.Clive Anderson, consultant dermatologist and ... address is part of a move to get Jamaicans ... of the island’s youth resort to bleaching or lightening ... ,Government health officials plan to launch a ...
Cached Medicine News:Health News:New Ideas on Developing Thought-Controlled Artificial Limbs 2Health News:Tamoxifen Discontinuation Rates Surprisingly High 2Health News:The Evolution of Costly Traits 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: